Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis
Status:
Unknown status
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Orthotopic liver transplantation (OLT) is currently the most effective method for end-stage
liver diseases. However, the critical shortage of donor organs, high cost, and the problem of
immune rejection limit its clinical application, and even some patients on the waiting list
will never survive to receive a matched liver. Stem cell transplantation instead of
conventional medical therapy or orthotopic liver transplantation will be a promising
alternate approach to regenerate damaged hepatic mass. Adult mesenchymal stem cells (MSCs)
are generally thought of as an autologous source of regenerative cells in previous studies.In
this study, the safety and efficacy of menstrual blood-derived stem cells transplantation for
patients with liver cirrhosis will be evaluated.
First Affiliated Hospital of Zhejiang University Wuhan General Hospital of Guangzhou Military Command Zhejiang General Hospital of Armed Police Zhejiang University Zhenjiang First People's Hospital